28
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Value of Serum Beta 2 Microglobulin as an Indicator of Early Relapse in Diffuse Large Cell Lymphoma

, , , , &
Pages 377-380 | Received 01 Jun 1992, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Teresa C. Gentile, Mark H. Wener, Gordon Starkebaum & Thomas P. Loughran. (1996) Humoral Immune Abnormalities in T-Cell Large Granular Lymphocyte Leukemia. Leukemia & Lymphoma 23:3-4, pages 365-370.
Read now

Articles from other publishers (8)

Jennifer Eatrides, Zachary Thompson, Ji-Hyun Lee, Celeste Bello & Samir Dalia. (2014) Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma. Annals of Hematology 94:2, pages 357-358.
Crossref
Milena Todorovi?Bela Balint, Bosko Andjelic, Ziv Radisavljevic & Biljana Mihaljevic. (2014) Switching to BCL-6 Negativity in Relapsed Diffuse Large B Cell Lymphoma Correlated with More Aggressive Disease Course. Indian Journal of Hematology and Blood Transfusion 30:4, pages 269-274.
Crossref
A. Softić, L. Begić, A. Halilbašić, T. Vižin & J. Kos. (2013) The Predictive Value of Cystatin C in Monitoring of B Non-Hodgkin Lymphomas: Relation to Biochemical and Clinical Parameters. ISRN Oncology 2013, pages 1-6.
Crossref
Yan Zhang, Min-Bin Chen, Xiao-Yan Zhou & Xiao-Nan Hong. (2013) Lymphotoxin Alpha (LTA) Polymorphism Is Associated with Prognosis of Non-Hodgkin?s Lymphoma in a Chinese Population. PLoS ONE 8:6, pages e66411.
Crossref
E. Seregni & E. Bombardieri. 1999. Nuclear Oncology. Nuclear Oncology 415 432 .
Costas NicolaidesSofia Dimou & Nicholas Pavlidis. (1998) Prognostic Factors in Aggressive Non‐Hodgkin's Lymphomas. The Oncologist 3:3, pages 189-197.
Crossref
Bertrand Coiffier. 1996. Advances in Lymphoma Research. Advances in Lymphoma Research 53 77 .
Bertrand Coiffier. 1995. Malignant Lymphomas: Biology and Treatment. Malignant Lymphomas: Biology and Treatment 103 125 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.